New gonorrhoea treatment hailed as breakthrough in fight against drug resistance | Gonorrhoea
Scientists praised a new treatment for Celon’s antibiotics, the first in three decades, which they said could help combat the global rise in drug -resistant infection.
Sexually transmitted infections can lead to serious complications if they are not treated immediately, especially for women, who can lead to an increase in the risk of pregnancy and infertility outside the uterus.
Drug resistant cases have increased rapidly in recent years, reducing treatment options. There is an urgent need for new treatments for gonorrhea, with no new antibiotics since the 1990s.
A study is now suggested that gepotidacin, an antibiotic used to treat urinary tract infections, can be used to combat infection, stavate drug -resistant conditions and improve patient experiences.
The stage-three results of the random control experience Posted in Lancet magazine It was presented at the annual conference of the European Association of Clinical Microbes and Infectious Diseases (ESCMID) in Vienna, Austria, on Monday. The experiment led researchers in the United Kingdom, the American, and patients from the United Kingdom, the United States, Australia, Germany, Mexico and Spain
In the study of 622 patients, researchers compared Gepotaidacin, which was taken as birth control pills, with standard treatment for syephraxone, injection, and Azithromycin, birth control pills.
They found that new birth control pills are effective as standard treatment in infection treatment.
It is important, Gepotidacin was effective against the strains of gonorrhea resistant to existing antibiotics. There were no severe or serious side effects associated with treatment for those treated with any of the medications, Lancet said.
The researchers said that the new treatment could be an important tool in fighting the rise of gonorrhea strains that have become resistant to standard therapy. In addition, treatment such as birth control pills alone without the need for injection is likely to improve the patient’s experiments and reduce the required health care resources.
The authors said that Gepotidacin “showed the absence of sifriaxon in addition to the Azithromycin” and “and showed” a new oral option for the genital gonorrhea. “
They added: “Gepotaidacin is a new oral treatment of antibacterial with the ability to become an alternative option for treating foodstuff infections.”
The authors also warned that the study was primarily looked at the genitals and that most patients were white men. Therefore, more research was needed to find out the effect of treatment on gonorrhea in the rectum and throat, and in women, children and other races.
Gonorrhea has become increasingly resistant to antibiotics, as health officials have previously warned that it could be inappropriate in the future.
Last year’s officials in England issued a warning About a high strength in cases.
There were 85,000 cases of gonorrhea diagnosed in England in 2023, the highest level since the records began in 1918.
The vast majority of cases can be treated. But there was an increase in people who were diagnosed with the resistance strings, which is a “first line” antibiotic that is usually used to treat infection.
Most of the affected people in England were in the twenties of two different sexes, and they gained infection abroad, although some had no travel date, UK health The security agency (Ukhsa) said.
Global health leaders have already warned Antimicrobial resistance is a major threat to humanity, as data showed that it has become a major cause of death all over the world and kills about 3,500 people every day.
More than 1.2 million-losers died millions of millions in 2019 as a direct result of antibiotic-resistant bacterial infections, according to a comprehensive estimate of 2022 of the global influence of antimicrobial resistance.
